What drove the OCX stock bounce after hours on 23 Feb 2026?

The after‑hours bounce to **$3.20** came with higher volume and short‑covering pressure. Technical relief in an oversold setup attracted buyers. Fundamental catalysts remain limited, so volume confirmation is key for OCX stock to sustain gains.

What are realistic price targets for OCX stock from here?

A conservative short‑term target is **$3.80**, implying **18.75%** upside from **$3.20**. A secondary bullish target near **$4.50** is possible with confirming volume. Downside risk could reach the low near **$1.92** if momentum fails.

How does Meyka AI view OCX stock for traders?

Meyka AI assigns OCX a **B+** score (72.80) and flags it as a buy for a tactical oversold bounce. The model stresses liquidity limits and recommends small position sizing and strict stop limits for NASDAQ‑listed OCX stock.

US Stocks

OCX OncoCyte NASDAQ After Hours 23 Feb 2026: $3.20 oversold bounce, watch $3.80

ByDanny Kontos February 24, 2026February 24, 2026

We saw OCX stock jump to $3.20 in after hours trading on 23 Feb 2026 after a sharp oversold bounce. OncoCyte Corporation (OCX) trades on the NASDAQ in the United States and moved higher on volume of 100,557 shares versus an average of 76,061. We view this as a short-term rebound in a low‑market‑cap biotechnology name, where technical relief and modest buying can push prices toward nearby resistance at $3.80. Meyka AI, an AI-powered market analysis platform, flagged OCX as a candidate for an oversold bounce trade given its recent downside and improving relative volume.